National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Cannabidiol (Epidyolex®) for the treatment of Tuberous Sclerosis Complex. HTA ID: 21024

Cannabidiol is indicated for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.


NCPE Assessment Process Complete
Rapid review commissioned 09/06/2021
Rapid review completed 08/07/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cannabidiol (Epidyolex®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.

The HSE has approved reimbursement following confidential price negotiations December 2021.